TA1 Research Guide

Full name: Thymosin Alpha-1 (TA1 - Clinical Form)

The clinical designation for Thymosin Alpha-1, used internationally as an immune modulator. Approved for hepatitis B/C and used adjunctively in immunocompromised patients.

How TA1 Works

Activates TLR2/9 on dendritic cells, promotes T-cell differentiation, and enhances cytokine-mediated immune signaling cascades.

Dosing Protocol

• Typical dose: 1.6 mg
• Frequency: 2x per week
• Duration: 6-12 months (chronic) or 4-8 weeks (general)
• Route: Subcutaneous injection

Reported Benefits

• Standardized immune enhancement
• Proven antiviral adjunct
• Cancer immunotherapy support
• Vaccine response enhancement

Potential Side Effects

• Injection site discomfort
• Mild erythema
• Transient flu-like symptoms

Research Citations

1. TA1 as vaccine adjuvant in elderly (2020) - Improved influenza vaccine antibody titers by 60% in immunosenescent elderly patients.
2. Thymalfasin in hepatocellular carcinoma (2019) - Improved overall survival when combined with standard chemotherapy in advanced HCC patients.

Related Immune Support Compounds

• Thymosin Alpha-1 - Full Profile
• Thymulin - Full Profile
• Lactoferrin - Full Profile
• Beta-Defensin - Full Profile
• Thymalin - Full Profile
• Vitamin D3 Injection - Full Profile

View full TA1 profile with 3D molecule viewer →